A proposed $23 million settlement has been reached in this class action lawsuit involving the antibiotic drug Solodyn®.  The lawsuit claims that Medicis Pharmaceutical Corp., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. (the “Defendants”) violated state competition (i.e. antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn off the market. The Defendants deny this. No one is claiming that Solodyn is unsafe or ineffective.  To settle the lawsuit, Medicis Pharmaceutical Corp. has agreed to pay $23 million into a Settlement Fund to settle all claims in the lawsuit brought on behalf of consumers and health insurers known as third-party payors.  To learn more about the terms of the proposed settlement, please click here.